Solventum Launches Attest™ eBowie-Dick Test System Revolutionizing Sterilization Assurance

Rhea-AI Summary

Solventum (NYSE: SOLV) has launched the Attest™ eBowie-Dick Test System, an innovative electronic sterilization testing solution that provides instant digital results and automated documentation. The system delivers definitive pass/fail results in under five seconds and integrates with hospital instrument tracking systems.

The new technology replaces traditional color-changing ink indicators used in steam dynamic-air removal sterilizers, reducing paper waste by 94% compared to conventional Bowie-Dick Test Packs. The system is now available in the United States through authorized distributors, with global rollout planned throughout 2025.

According to Chris Barry, executive vice president and group president of Medical Surgical at Solventum, the eBowie-Dick System revolutionizes sterilization testing by reducing processing times, eliminating result variability, and providing advanced analytics capabilities.

Positive

• Innovative product launch that modernizes sterilization testing process
• 94% reduction in paper waste compared to traditional methods
• Integration capability with hospital instrument tracking systems
• Faster results delivery (under 5 seconds) compared to traditional methods

Negative

• None.

Insights

Medical Technology Expert

Solventum's new Attest™ eBowie-Dick Test System represents a significant advancement in sterilization monitoring technology for hospitals. The innovation transforms a traditionally manual, subjective process into a digital, objective one with immediate results in under five seconds.

The technical improvement is substantial - eliminating visual interpretation variability while enabling digital record integration with hospital instrument tracking systems. This addresses two critical pain points in sterile processing departments: workflow efficiency and documentation compliance.

From a clinical perspective, sterilization monitoring is mission-critical for infection prevention. By digitizing this process, Solventum reduces human error risks while potentially improving compliance rates through automated documentation. The 94% reduction in paper waste also aligns with healthcare sustainability initiatives.

What's particularly valuable is how this product leverages Solventum's expertise at the intersection of material science, healthcare, and data - creating differentiation in a market where innovation has been incremental. By digitizing analog processes, they're building infrastructure for potential future analytics capabilities.

While the financial impact remains unquantified, this launch strengthens Solventum's competitive position in the infection prevention segment of medical devices. The planned global rollout throughout 2025 suggests confidence in market receptivity and regulatory pathway clarity across multiple jurisdictions.

Financial Analyst

This product launch demonstrates Solventum's strategic focus on digitizing analog healthcare processes - a high-margin opportunity with potential for recurring revenue. The eBowie-Dick system creates value through several financial mechanisms:

First, workflow efficiency improvements typically justify premium pricing in healthcare settings where labor costs dominate operational expenses. By reducing processing times and eliminating manual documentation, Solventum can likely command higher prices while delivering cost savings to customers.

Second, the digital integration capability creates switching costs and potential recurring revenue streams. Once integrated into hospital instrument tracking systems, customers face significant barriers to changing vendors, enhancing customer retention and lifetime value.

Third, digital capabilities enable advanced analytics which could become a future upsell opportunity and competitive moat. The reference to "advanced analytics not possible with today's tests" signals potential subscription revenue models beyond the initial hardware sale.

The sustainability angle (94% waste reduction) also positions the product favorably for procurement criteria increasingly factoring ESG considerations. The global rollout throughout 2025 indicates a systematic approach to market expansion that should drive incremental revenue growth over multiple quarters.

While the immediate revenue impact is likely modest relative to Solventum's $13.3 billion market cap, this launch exemplifies their innovation strategy in high-value medical consumables and strengthens their competitive positioning as they establish their post-3M identity.

ST. PAUL, Minn., March 12, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV), formerly 3M Health Care, today announced the launch of the Attest™ eBowie-Dick Test System (eBowie-Dick System), an electronic test card and auto-reader for sterilization testing that eliminates the need for visual interpretation of results and manual documentation.

In less than five seconds, the eBowie-Dick System's simple "pass" or "fail" digital display provides definitive test results and creates an automated record that can be integrated into a hospital's instrument tracking system, eliminating the need to scan analog test results.

Traditional tests for steam dynamic-air removal sterilizers use a color-changing ink indicator to evaluate the efficacy of air removal and detect leaks in the sterilizer. The ink indicator is tucked between layers of a paper packet. The paper is discarded when the ink indicator is removed from the packet to assess the test results.

The eBowie-Dick Test System can reduce the paper waste from Bowie-Dick tests entering a hospital's waste stream by 94%^* compared to paper waste generated by traditional Bowie-Dick Test Packs.

"Our new eBowie-Dick System revolutionizes sterilization testing by reducing processing times, eliminating the variability inherent to traditional methods, and the device's software capabilities provide advanced analytics not possible with today's tests," said Chris Barry, executive vice president, group president, Medical Surgical, Solventum. "Through digitization, Solventum is saving sterilization assurance professionals time and reducing waste to help create a more sustainable future."

The eBowie-Dick System is now available in the United States from authorized distribution partners and will roll out globally throughout 2025^**.

About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.

Forward-Looking Statements
This news release contains forward-looking information about Solventum's financial results, estimates, and business prospects that involve substantial risks and uncertainties. In particular, statements regarding the future performance of Solventum, including guidance for 2024, are forward-looking statements. You can identify these statements by the use of words such as "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "guidance," "intends," "may," "outlook," "plans," "projects," "seeks," "sees," "should," "targets," "will," "would," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) the effects of, and changes in, worldwide economic, political, regulatory, international, trade and geopolitical conditions, natural disasters, war, public health crises, and other events beyond Solventum's control; (2) operational execution risks; (3) damage to our reputation or our brands; (4) risks from acquisitions, strategic alliances, divestitures and other strategic events; (5) Solventum's business dealings involving third-party partners in various markets; (6) Solventum's ability to access the capital and credit markets and changes in Solventum's credit ratings; (7) exposure to interest rate and currency risks; (8) the highly competitive environment in which Solventum operates and consolidation in the healthcare industry; (9) reduction in customers' research budgets or government funding; (10) the timing and market acceptance of Solventum's new product and service offerings; (11) ongoing working relationships with certain key healthcare professionals; (12) changes in reimbursement practices of governments or private payers or other cost containment measures; (13) Solventum's ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions, and disruptive factors; (14) legal and regulatory proceedings and legal compliance risks (including third-party risks) with regards to antitrust, Foreign Corrupt Practices Act (FCPA) and other anti-bribery laws, environmental laws, anti-kickback and false claims laws, privacy laws, tax laws, and other laws and regulations in the United States and other countries in which Solventum operates; (15) potential liabilities related to a broad group of perfluoroalkyl and polyfluoroalkyl substances, collectively known as "PFAS"; (16) risks related to the highly regulated environment in which Solventum operates; (17) risks associated with product liability claims; (18) climate change and measures to address climate change; (19) security breaches and other disruptions to information technology infrastructure; (20) Solventum's failure to obtain, maintain, protect, or effectively enforce its intellectual property ("IP") rights; (21) pension and postretirement obligation liabilities; (22) any failure by the 3M Company ("3M") to perform any of its obligations under the various separation agreements in connection with the separation from 3M (the "Spin-Off"); (23) any failure to realize the expected benefits of the Spin-Off, and/or that the Spin-Off will not be completed within the expected time frame, on the expected terms or at all; (24) a determination by the IRS or other tax authorities that the distribution or certain related transactions should be treated as taxable transactions; (25) expected financing transactions undertaken in connection with the separation and risks associated with additional indebtedness; (26) the risk that incremental costs of operating on a standalone basis (including the loss of synergies), costs of restructuring transactions and other costs incurred in connection with the separation will exceed Solventum's estimates; and (27) the impact of the Spin-Off on its businesses and the risk that the Spin-Off may be more difficult, time-consuming or costly than expected, including the impact on its resources, systems, procedures and controls, diversion of management's attention and the impact on relationships with customers, suppliers, employees and other business counterparties.

Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located under "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in Solventum's periodic reports on file with the U.S. Securities & Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

*Compared to waste generated by 3M Bowie-Dick paper test packs. Waste mass based on eBowie-Dick 10135B product and packaging case weight, with percent calculated on per test basis.
**Some countries may be delayed due to additional local regulatory requirements

View original content to download multimedia:https://www.prnewswire.com/news-releases/solventum-launches-attest-ebowie-dick-test-system-revolutionizing-sterilization-assurance-302399513.html

SOURCE Solventum

FAQ

What is Solventum's new Attest eBowie-Dick Test System and how does it work?

The Attest eBowie-Dick Test System is an electronic test card and auto-reader that provides pass/fail results in under 5 seconds for sterilization testing, eliminating manual interpretation and documentation needs.

How much paper waste reduction does SOLV's new eBowie-Dick System achieve?

The system reduces paper waste by 94% compared to traditional Bowie-Dick Test Packs in hospital waste streams.

When will SOLV's eBowie-Dick Test System be available globally?

The system is currently available in the United States through authorized distributors, with global rollout planned throughout 2025.

What are the main advantages of SOLV's new eBowie-Dick System over traditional methods?

Key advantages include instant digital results, automated documentation, reduced processing times, elimination of result variability, and advanced analytics capabilities.

How does SOLV's eBowie-Dick System integrate with existing hospital systems?

The system creates automated records that can be integrated directly into a hospital's instrument tracking system, eliminating the need to scan analog test results.